Ocular Therapeutix, Inc last reported quarterly results on Aug 3, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $13.5 million (+0.1% year over year) and diluted EPS of -$0.35. It usually reports 34–36 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 3, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Tuesday. Based on last year's release for the same quarter on Nov 4, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 34–36 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 3, 2026
34 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
13
+0.1%
|
-79
-16.1%
|
-0.35
+10.3%
|
|
May 5, 2026
35 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
11
+0.8%
|
-89
-38.3%
|
-0.40
-5.3%
|
|
Feb 5, 2026
36 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
13
-22.4%
|
-65
-33.6%
|
-0.29
-0.9%
|
|
Nov 4, 2025
35 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
15
-5.7%
|
-69
-90.2%
|
-0.38
-72.7%
|
|
Aug 5, 2025
36 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
13
-18.1%
|
-68
-54.9%
|
-0.39
-50.0%
|
|
May 5, 2025
35 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
11
-27.6%
|
-64
+1.2%
|
-0.38
+22.4%
|
|
Mar 3, 2025
62 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
17
+15.4%
|
-48
-65.6%
|
-0.29
+11.1%
|
|
Nov 14, 2024
45 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
15
+2.3%
|
-36
-6972.3%
|
-0.22
+12.0%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- OCUL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Bedford, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1393434
- Former names
- I-THERAPEUTIX INC (until Jul 2, 2009)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.